6,531 followers
New research: Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma: Background In this study, compared to sunitinib as one of the available treatment options, we aimed to… https://t.co/